Lamise Rajjoub, MD
Ophthalmic Plastic and Reconstructive Surgery · Washington, DCNPI 1225327240
Payments from drug & device makers
Across 96 payments — averaging $511.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$49K
- Galderma Laboratories, L.p.$172
- Kala Pharmaceuticals, Inc.$142
- Merz North America, Inc.$52
- Sun Pharmaceutical Industries Inc.$37
- Rxsight Inc$37
- plus $82 from 4 others
What the payments were for
- Consulting fees$5,10010%
- Speaking & faculty fees$39,10080%
- Travel & lodging$2,0944%
- Food & beverage$2,7796%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 80 | $48,560 |
| Galderma Laboratories, L.p. | 5 | $172 |
| Kala Pharmaceuticals, Inc. | 2 | $142 |
| Merz North America, Inc. | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Rxsight Inc | 1 | $37 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Carl Zeiss Meditec USA, Inc. | 1 | $21 |
| Alcon | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 51 | $2,136 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 153 | $1,648 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $641 |
| Doxycycline Hyclate | 33 | $630 |
| Prednisolone Acetate | 18 | $530 |
| ErythromycinErythromycin Base | 13 | $114 |
| Tramadol Hcl | 30 | $24 |
| Diazepam | 15 | $12 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Washington
- Erin BlackWashington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.